Fox Chase Cancer Center News

PHILADELPHIA (June 18, 2021)—A study from researchers at Fox Chase Cancer Center suggests that some breast cancer patients may be able to forgo certain testing procedures after neoadjuvant chemotherapy, which is chemotherapy given before other treatment, without increasing their risk of cancer returning.

PHILADELPHIA (June 18, 2021)—Fox Chase Cancer Center’s main, Buckingham, and East Norriton campuses have been awarded a three-year term of reaccreditation in radiation oncology as the result of a recent review by the American College of Radiology (ACR).

PHILADELPHIA (June 15, 2021) – Researchers at Fox Chase Cancer Center recently used RNA next-generation sequencing of a fine-needle aspiration (FNA) sample to identify a novel fusion gene indicative of pleomorphic adenoma (PA), a common benign salivary gland tumor.

PHILADELPHIA (June 9, 2021)—A 70-year-old woman with Hodgkin Lymphoma being treated at Fox Chase Cancer Center had increased FDG uptake in her lymph nodes two days after receiving a COVID-19 vaccination. FDG is short for fluorodeoxyglucose, a radiolabeled sugar used during positron emission tomography (PET) scans.

PHILADELPHIA (June 9, 2021)—There’s growing evidence that statins can offer an effective treatment for medulloblastoma, a childhood brain cancer, without the severe side effects of other chemotherapy drugs. Now a new study by researchers at Fox Chase Cancer Center explains why.

PHILADELPHIA (June 9, 2021)—Researchers at Fox Chase Cancer Center investigating psychological distress in patients with metastatic cancer enrolling in phase 1 clinical trials found that although physical stressors did not strongly relate to patients’ overall level of distress, emotional, family, and practical stressors did.

PHILADELPHIA (June 8, 2021)—Researchers at Fox Chase Cancer Center have developed a model that predicts disease recurrence and survival in patients with kidney cancer more accurately than other models currently in use.

PHILADELPHIA (June 4, 2021) – A large retrospective study of real-world patients with renal cell carcinoma (RCC) showed similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they are treated with the combination of axitinib plus pembrolizumab or ipilimumab plus nivolumab.